An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis

Antonio M Jimenez Jimenez; Marcos De Lima; Krishna V Komanduri; Trent P Wang; Mei-Jie Zhang; Karen Chen; Hisham Abdel-Azim; Muhammad Bilal Abid; Mahmoud Aljurf; Hassan Alkhateeb; Amer Assal; Ulrike Bacher; Frédéric Baron; Minoo Battiwalla; Amer Beitinjaneh; Nelli Bejanyan; Vijaya Raj Bhatt; Michael Byrne; Jean-Yves Cahn; Mitchell Cairo; Paul Castillo; Edward Copelan; Zachariah DeFilipp; Miguel Angel Diaz Perez; Mahmoud Elsawy; Robert Peter Gale; Biju George; Michael R Grunwald; Gerhard C Hildebrandt; William J Hogan; Christopher G Kanakry; Ankit Kansagra; Mohamed A Kharfan-Dabaja; Nandita Khera; Maxwell M Krem; Aleksandr Lazaryan; Joseph Maakaron; Rodrigo Martino; Joseph McGuirk; Fotios V Michelis; Giuseppe Milone; Asmita Mishra; Hemant S Murthy; Alberto Mussetti; Sunita Nathan; Taiga Nishihori; Richard F Olsson; Neil Palmisiano; Sagar Patel; Ayman Saad; Sachiko Seo; Akshay Sharma; Melhem Solh; Leo F Verdonck; Baldeep Wirk; Jean A Yared; Mark Litzow; Partow Kebriaei; Christopher S Hourigan; Wael Saber; Daniel Weisdorf

doi:10.1038/s41409-021-01450-3

Back

An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis

Journal article

Peer reviewed

An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis

Antonio M Jimenez Jimenez, Marcos De Lima, Krishna V Komanduri, Trent P Wang, Mei-Jie Zhang, Karen Chen, Hisham Abdel-Azim, Muhammad Bilal Abid, Mahmoud Aljurf, Hassan Alkhateeb, …

Bone marrow transplantation (Basingstoke), Vol.56(12), pp.3068-3077

2021-12

DOI: https://doi.org/10.1038/s41409-021-01450-3

PMID: 34584240

Abstract

Cytogenetic and molecular abnormalities are known to influence post-transplant outcomes in acute myeloid leukemia (AML) but data assessing the prognostic value of combined genetic models in the HCT setting are limited. We developed an adapted European LeukemiaNet (aELN) risk classification based on available genetic data reported to the Center for International Blood and Marrow Transplant Research, to predict post-transplant outcomes in 2289 adult AML patients transplanted in first remission, between 2013 and 2017. Patients were stratified according to aELN into three groups: favorable (Fav, N = 181), intermediate (IM, N = 1185), and adverse (Adv, N = 923). Univariate analysis demonstrated significant differences in 2-year overall survival (OS) (Fav: 67.7%, IM: 64.9% and Adv: 53.9%; p < 0.001); disease-free survival (DFS) (Fav: 57.8%, IM: 55.5% and Adv: 45.3; p < 0.001) and relapse (Fav: 28%, IM: 27.5% and Adv: 37.5%; p < 0.001). Multivariate analysis (MVA) revealed no differences in outcomes between the Fav and IM groups, thus they were combined. On MVA, patients in the Adv risk group had the highest risk of relapse (HR 1.47 p ≤ 0.001) and inferior DFS (HR 1.35 p < 0.001) and OS (HR 1.39 p < 0.001), even using myeloablative conditioning or in those without the pre-HCT measurable-residual disease. Novel approaches to mitigate relapse in this high-risk group are urgently needed.

Metrics

3 Record Views

9 Times Cited - Web of Science

See more details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.103 Blood Disorders; 1.103.155 Acute Myeloid Leukemia
Web Of Science research areas: Biophysics; Hematology; Immunology; Oncology; Transplantation
ESI research areas: Immunology

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis
Creators: Antonio M Jimenez Jimenez - University of Miami
Marcos De Lima - University Hospitals Case Medical Center
Krishna V Komanduri - University of Miami
Trent P Wang - University of Miami
Mei-Jie Zhang - Medical College of Wisconsin
Karen Chen - Medical College of Wisconsin
Hisham Abdel-Azim - Division of Hematology, Oncology and Blood & Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
Muhammad Bilal Abid - Medical College of Wisconsin
Mahmoud Aljurf - Department of Oncology, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia
Hassan Alkhateeb - Mayo Clinic Rochester, Rochester, MN, USA
Amer Assal - Columbia University
Ulrike Bacher - University of Bern
Frédéric Baron - University of Liège
Minoo Battiwalla - Sarah Cannon
Amer Beitinjaneh - University of Miami
Nelli Bejanyan - Moffitt Cancer Center
Vijaya Raj Bhatt - University of Nebraska Medical Center
Michael Byrne - Vanderbilt University Medical Center
Jean-Yves Cahn - Department of Hematology, CHU Grenoble Alpes, Université Grenoble Alpes, Grenoble, France
Mitchell Cairo - STEM
Paul Castillo - UF Health Shands Children's Hospital, Gainesville, FL, USA
Edward Copelan - Levine Cancer Institute
Zachariah DeFilipp - Massachusetts General Hospital
Miguel Angel Diaz Perez - Hospital Infantil Universitario Niño Jesús
Mahmoud Elsawy - Dalhousie University
Robert Peter Gale - Imperial College London
Biju George - Christian Medical College
Michael R Grunwald - Levine Cancer Institute
Gerhard C Hildebrandt - Markey Cancer Center
William J Hogan - Division of Hematology/BMT, Mayo Clinic, Rochester, MN, USA
Christopher G Kanakry - National Institutes of Health
Ankit Kansagra - Southwestern Medical Center
Mohamed A Kharfan-Dabaja - Division of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL, USA
Nandita Khera - Department of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, USA
Maxwell M Krem - Markey Cancer Center
Aleksandr Lazaryan - Moffitt Cancer Center
Joseph Maakaron - University of Minnesota
Rodrigo Martino - Divison of Clinical Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Joseph McGuirk - The University of Kansas Cancer Center
Fotios V Michelis - Princess Margaret Cancer Centre
Giuseppe Milone - Azienda Ospedaliera Universitaria Policlinico-San Marco, Catania, Italy
Asmita Mishra - Moffitt Cancer Center
Hemant S Murthy - Division of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL, USA
Alberto Mussetti - Ajuntament de L’Hospitalet
Sunita Nathan - Rush University Medical Center
Taiga Nishihori - Moffitt Cancer Center
Richard F Olsson - Uppsala University
Neil Palmisiano - Sidney Kimmel Cancer Center
Sagar Patel - Huntsman Cancer Institute
Ayman Saad - Division of Hematology, Ohio State University, Columbus, OH, USA
Sachiko Seo - Dokkyo Medical University
Akshay Sharma - St. Jude Children's Research Hospital
Melhem Solh - Northside Hospital
Leo F Verdonck - Isala
Baldeep Wirk - Hershey
Jean A Yared - University of Maryland, Baltimore
Mark Litzow - Division of Hematology and Transplant Center, Mayo Clinic Rochester, Rochester, MN, USA
Partow Kebriaei - The University of Texas MD Anderson Cancer Center
Christopher S Hourigan - National Heart Lung and Blood Institute
Wael Saber - Medical College of Wisconsin
Daniel Weisdorf - University of Minnesota
Publication Details: Bone marrow transplantation (Basingstoke), Vol.56(12), pp.3068-3077
Grant note: R01 CA152108 / NCI NIH HHS U01 AI126612 / NIAID NIH HHS
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
PMID: 34584240
Record Identifier: 991031660122202976